An amendment to this paper has been published and can be accessed via the original article.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346663 | PMC |
| http://dx.doi.org/10.1186/s12874-020-01028-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Concentration-QT modeling demonstrates that the selective mineralocorticoid receptor modulator, balcinrenone (AZD9977), does not prolong QT interval.
CPT Pharmacometrics Syst Pharmacol
November 2024
Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Article Synopsis
- Balcinrenone (AZD9977) is a selective mineralocorticoid receptor modulator being tested for heart failure treatment alongside dapagliflozin, particularly for patients with impaired kidney function.
- A study involving 62 healthy male participants evaluated various oral doses of balcinrenone to assess its impact on the QT interval using electrocardiograms and plasma concentration measurements.
- The analysis suggested that balcinrenone does not significantly prolong the QT interval, even at high therapeutic doses, remaining below the regulatory concern threshold.
Increased Genetic Risk for β-Cell Failure Is Associated With β-Cell Function Decline in People With Prediabetes.
Diabetes
August 2024
Diabetes Unit, Massachusetts General Hospital, Boston, MA.
Partitioned polygenic scores (pPS) have been developed to capture pathophysiologic processes underlying type 2 diabetes (T2D). We investigated the association of T2D pPS with diabetes-related traits and T2D incidence in the Diabetes Prevention Program. We generated five T2D pPS (β-cell, proinsulin, liver/lipid, obesity, lipodystrophy) in 2,647 participants randomized to intensive lifestyle, metformin, or placebo arms.
View Article and Find Full Text PDFThe myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses.
Pharmacol Res Perspect
April 2024
Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Article Synopsis
- Mitiperstat is being studied as a treatment for heart failure, non-alcoholic steatohepatitis, and chronic obstructive pulmonary disease, focusing on its safety regarding QT-interval prolongation.
- In a phase 1 study, healthy male volunteers received varying doses of mitiperstat, and researchers assessed the drug's impact on QT intervals using concentration-QT modeling.
- The findings indicated that mitiperstat does not pose a risk for QT-interval prolongation at therapeutic levels, as the predicted effect remains below regulatory concern thresholds.
Triangular prismatic JJ stent does not cause more discomfort than tubular ones: a randomised controlled trial comparison.
World J Urol
February 2024
Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, 1665 Kongjiang Rd. Yangpu District, Shanghai, 200092, China.
Objective: To compare the stent-related symptoms (SRS) of three commonly used, readily accessible ureteric JJ stents after uncomplicated flexible ureteroscopic lithotripsy (FURL), in a prospective randomised controlled single-blind parallel-group study, in order to see whether structural difference might influence SRS.
Patients And Methods: Patients undergoing FURL were randomised into three groups: the Cook Group received conventional 6 F Cook Universa Soft JJ stents as control, the Kang Yi Bo (KYB) Group received 6 F KYB anti-reflux JJ stents, and the Urovision Group received 7 F Urovision Visiostar ESWL JJ stents. The ureteric stent symptom questionnaire (USSQ) was administered at 1 week, 4 weeks (before stent removal), and 5 weeks (one week after stent removal as baseline evaluation) after stent insertion.
A randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery for open globe trauma - the ASCOT study.
Health Technol Assess
July 2023
Imperial College Clinical Trials Unit, Imperial College London, London, UK.
Background: Eyes sustaining open globe trauma are at high risk of severe visual impairment. Proliferative vitreoretinopathy is the most common cause of retinal detachment and visual loss in eyes with open globe trauma. There is evidence from experimental studies and pilot clinical trials that the use of adjunctive steroid medication triamcinolone acetonide can reduce the incidence of proliferative vitreoretinopathy and improve outcomes of surgery for open globe trauma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!